venous%20thromboembolism%20-%20prevention
VENOUS THROMBOEMBOLISM - PREVENTION
Venous thromboembolism is comprised of pulmonary embolism and deep venous thrombosis and is associated with significant morbidity and mortality.
All patients admitted for major trauma, surgery or acute medical illness should be assessed for risk of venous thromboembolism and bleeding before starting prophylaxis for venous thromboembolism.
Decision on which type of prophylaxis to be given must be individualized for each patient.

Venous Thromboembolism - Prevention Drug Information

Drug Information

Indication: DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvu...

Indication: 2.5 mg: Prevention of venous thromboembolic events (VTE) in patients undergoing major orthopaedic lower limbs ...

Indication: Transient ischaemic attacks, secondary prevention of MI. Platelet aggregation inhibitor for prophylaxis agains...

Indication: AMI. Prevention of heart attack in certain high-risk patients; prevention of CVA after transient ischaemic att...

Indication: Prophylaxis & treatment of venous thrombosis & pulmonary embolism. MI & arterial embolism. Prevent...

Indication: 10-mg tab Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replace...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Dec 2020

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.